NASDAQ · LPCN
Healthcare · Biotechnology
$2.10
Up+$0.03 (+1.45%)
Updated Oct 7, 2026, 3:13 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LPCN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
LPCN closed at $2.10 after 21 trading sessions, down 11.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.08 | $2.10 | $2.0699 | $2.10 | 12.78K |
| Oct 5, 2026 | $2.07 | $2.135 | $2.07 | $2.07 | 19.76K |
| Oct 2, 2026 | $2.08 | $2.13 | $2.05 | $2.05 | 38.94K |
| Oct 1, 2026 | $2.19 | $2.19 | $2.07 | $2.07 | 71.21K |
| Sep 30, 2026 | $2.14 | $2.25 | $2.08 | $2.20 | 31.37K |
| Sep 29, 2026 | $2.09 | $2.21 | $2.09 | $2.16 | 24.26K |
| Sep 28, 2026 | $2.07 | $2.21 | $2.06 | $2.09 | 34.44K |
| Sep 25, 2026 | $2.12 | $2.1824 | $2.06 | $2.10 | 32.77K |
| Sep 24, 2026 | $2.10 | $2.1778 | $2.08 | $2.09 | 32.64K |
| Sep 23, 2026 | $2.15 | $2.18 | $2.12 | $2.12 | 90.87K |
| Sep 22, 2026 | $2.13 | $2.22 | $2.12 | $2.16 | 64.4K |
| Sep 21, 2026 | $2.19 | $2.25 | $2.18 | $2.24 | 16.72K |
| Sep 18, 2026 | $2.20 | $2.25 | $2.12 | $2.21 | 48.49K |
| Sep 17, 2026 | $2.16 | $2.22 | $2.10 | $2.22 | 43.87K |
| Sep 16, 2026 | $2.23 | $2.235 | $2.15 | $2.16 | 64.03K |
| Sep 15, 2026 | $2.20 | $2.24 | $2.15 | $2.185 | 50.45K |
| Sep 14, 2026 | $2.20 | $2.2699 | $2.15 | $2.22 | 27.32K |
| Sep 11, 2026 | $2.29 | $2.30 | $2.25 | $2.27 | 10.4K |
| Sep 10, 2026 | $2.315 | $2.345 | $2.25 | $2.25 | 9.39K |
| Sep 9, 2026 | $2.34 | $2.3525 | $2.25 | $2.25 | 4.81K |
| Sep 8, 2026 | $2.39 | $2.40 | $2.345 | $2.36 | 21.14K |
The latest Smart Investors Daily articles mentioning LPCN.
Company
Market Activity
Research & News
LPCN research
Company profile and research snapshot.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 6, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Benzinga · Sep 21, 2026
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.
Yahoo · Sep 14, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment, targeting the need for rapid symptom relief with a short oral regimen. Lipocine believes this potential profile could address a substantial unmet need in PPD
Yahoo · Sep 10, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LPCN.
